Market Overview

FibroGen Upgraded By Mizuho On Continued R&D Progress

Share:
FibroGen Upgraded By Mizuho On Continued R&D Progress
Related FGEN
The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut
The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default

A combination of slightly better-than-expected first-quarter earnings and potential regulatory approval on the horizon have solidified one analysts faith in FibroGen Inc (NASDAQ: FGEN) moving towards the end of the year.

The Analyst

Mizuho’s Difei Yang upgraded shares of FibroGen from Neutral to Buy with a $61 price target.

The Thesis

The company recently reported Q1 earnings. Earnings came in at a loss of 50 cents per share, roughly in line with the consensus estimate, while sales of $31.925 million beat the $27.15 million estimate.

More notably, FibroGen has continued to make progress on its research and development pipelines. In particular, the company’s Roxadustat stood out the Yang. Top-line Phase III data is expected in Q4 this year, and the drug has received priority review from the China FDA, with potential approval arriving by the year’s end.

“We believe the company is likely to gain the first approval in new generation anemia drugs,” Yang said in a note.

The analyst is also looking forward to an update on Pamrevlumab by mid-year 2018, and expects significant upside if it can reproduce its Phase II results in the planned Phase III trial.

Price Action

Shares of FibroGen closed up 2.8 percent at $51.10 on Tuesday.

Related Links:

Benzinga's Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway

The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Latest Ratings for FGEN

DateFirmActionFromTo
Oct 2018Leerink SwannMaintainsOutperformOutperform
May 2018MizuhoUpgradesNeutralBuy
Oct 2017MizuhoInitiates Coverage OnNeutral

View More Analyst Ratings for FGEN
View the Latest Analyst Ratings

Posted-In: Difei Yang mizuho PamrevlumabAnalyst Color Biotech Upgrades Analyst Ratings General Best of Benzinga

 

Related Articles (FGEN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ACBIKeefe Bruyette & WoodsUpgrades21.0
COTYBMO CapitalUpgrades12.0
ECCOppenheimerDowngrades0.0
VYGRRaymond JamesUpgrades0.0
ATNXJP MorganUpgrades15.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

The Biggest Mistake Founders Make When Pitching A Venture Capitalist

7 Stocks Moving In Tuesday's After-Hours Session